Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: A retrospective study of 574 patients

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Inciura, Arturas ^a   Simavicius, Andrius ^b   Juozaityte, Elona ^a   Kurtinaitis, Juozas ^c   Nadisauskiene, Ruta ^a   Svedas, Eimantas ^a   Kajenas, Skirmantas ^a  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^b Clinic of Obstetrics and Gynaecology   (Lithuania)

^c VILNIUS UNIVERSITY   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CANCER ADJUVANT THERAPY; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HOSPITAL ADMISSION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VALIDATION PROCESS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33746951957     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-153     Document Type: Article

References (27)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
3. Inciura A, Juozaityte E, Nadisauskiene R, Cigriejiene VM, Kajenas S, Vaitkiene D, Vaidotiene L, Simavicius A: Surgical treatment of advanced epithelial ovarian cancer. Medicina 2004, 40:205-215.
4. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH: A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study [abstract]. Proc Am Soc Clin Oncol 2002, 21:201a.
5. Chambers JT, Chambers SK, Voynick IM, Schwartz PE: Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990, 37:327-331.
6. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Camatte S, Duvillard P, Castaigne D: Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 2003, 14:74-77.
7. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V, Humblet Y, Donnez J, Machiels JP: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 2003, 90:163-169.
8. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 2001, 92:2585-2591.
9. Onnis A, Marchetti M, Padovan P, Castellan L: Neoadjuvant chemoterapy in advanced ovarian cancer. Eur J Gynaecol Oncol 1996, 17:393-396.
10. Shimizu Y, Hasumi K: Treatment of stage III and IV ovarian cancer: is neoadjuvant chemotherapy effective? Nippon Sanka Fujinka Gakkai Zasshi 1993, 45:1007-1014.
11. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M, van Dam P: Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Sem Oncol 2000, 27:31-36.
12. Surwit E, Childers J, Atlas I: Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996, 6:356-361.
13. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP: Neoadjuvant chemoterapy for advanced ovarian cancer: long term survival. Gynecol Oncol 1999, 72:93-99.
14. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT: Neoadjuvant chemoterapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991, 42:146-150.
15. Lim JT, Green JA: Neoadjuvant carboplatin and ifosfamide chemoterapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol 1993, 5:198-202.
16. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G: Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetr Gynecol 1989, 73:61-65.
17. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, Lhomme C, Scherer C, Tigaud JD, Benchaib M, Fourme E, Castaigne D, Querleu D, Dargent D: Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001, 91:2329-2334.
18. Recchia F, De Filipps S, Rosselli M, Saggio G, Carta G, Rea S: Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaecol Oncol 2001, 22:287-291.
19. Loizzi V, Cormio G, resta L, Rossi CA, Di Gilio AR, Cuccovillo A, Selvaggi L: Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int J Gynecol Cancer 2005, 15:217-223.
20. Kayikcioglu F, Kose MF, Boran N, Caliskan E, Tulunay G: Neoadjuvant chemotherapy of primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001, 11:466-470.
21. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, Lhomme C, Duvillard P, Castaigne D: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 2003, 197:955-963.
22. Ivanov S, Ivanov S, Khadzhiolov N: Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy. Akush Ginekol 2004, 43:17-9.
23. Hoskins WJ: Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993, 71:1534-1540.
24. Vergote IB, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P: Neoadjuvant chemoterapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 258 patients. Gynecol Oncol 1998, 71:431-436.
25. Huober J, Meyer A, Wagner U, Wallwiener D: The role of neoadjuvant chemoterapy and interval laparatomy in advanced ovarian cancer. J Cancer Res Clin Oncol 2002, 128:153-160.
26. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Heintz AP, van Lent M, Trimbos JB, Bouma J, Vermorken JB: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987, 5:1157-11681
27. Hegazy M, Hegazi R, Elshafei M, Elshamy M, Eltatoongy M, Halim A: Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol 2005, 3:57.